Oncology biotech Accent raises $75M to enter the clinic

Ac­cent Ther­a­peu­tics raised $75 mil­lion in Se­ries C fund­ing from three Big Phar­ma com­pa­nies and oth­er in­vestors to test its first two pre­ci­sion on­col­o­gy small mol­e­cules in ear­ly clin­i­cal tri­als.

The raise, led by glob­al as­set firm Mi­rae’s new US af­fil­i­ate, which is ded­i­cat­ed to life sci­ences, oc­curred near­ly four years af­ter the start­up dis­closed a $63 mil­lion Se­ries B in the ear­ly days of the pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.